{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:17:51Z","timestamp":1740147471347,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["1U01AA021908-01","1U01AA020821"],"award-info":[{"award-number":["1U01AA021908-01","1U01AA020821"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008318","name":"AEEH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008318","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s12072-016-9768-8","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T13:07:28Z","timestamp":1473944848000},"page":"851-853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alcoholic hepatitis: should we combine old drugs for better results?"],"prefix":"10.1007","volume":"10","author":[{"given":"Joaquin","family":"Cabezas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"9768_CR1","unstructured":"WHO. Global status report on alcohol and health 2014. http:\/\/apps.who.int\/iris\/bitstream\/10665\/112736\/1\/9789240692763_eng.pdf?ua=1"},{"key":"9768_CR2","doi-asserted-by":"crossref","unstructured":"Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141(5):1572\u20131785","DOI":"10.1053\/j.gastro.2011.09.002"},{"key":"9768_CR3","doi-asserted-by":"crossref","unstructured":"Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360(26):2758\u20132769","DOI":"10.1056\/NEJMra0805786"},{"key":"9768_CR4","doi-asserted-by":"crossref","unstructured":"Michelena J, Altamirano J, Abraldes JG, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 2015;62(3):762\u2013772","DOI":"10.1002\/hep.27779"},{"key":"9768_CR5","doi-asserted-by":"crossref","unstructured":"Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365(19):1790\u20131800","DOI":"10.1056\/NEJMoa1105703"},{"key":"9768_CR6","doi-asserted-by":"crossref","unstructured":"Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. New Engl J Med 2015;372(17):1619\u20131628","DOI":"10.1056\/NEJMoa1412278"},{"key":"9768_CR7","doi-asserted-by":"crossref","unstructured":"Mathurin P, O\u2019Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60(2):255\u2013260","DOI":"10.1136\/gut.2010.224097"},{"key":"9768_CR8","doi-asserted-by":"crossref","unstructured":"Porter HP, Simon FR, Pope CE 2nd, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971;284(24):1350\u20131355","DOI":"10.1056\/NEJM197106172842404"},{"key":"9768_CR9","doi-asserted-by":"crossref","unstructured":"Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37(4):448\u2013455","DOI":"10.1016\/S0168-8278(02)00230-1"},{"key":"9768_CR10","doi-asserted-by":"crossref","unstructured":"Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014;109(9):1417\u20131423","DOI":"10.1038\/ajg.2014.154"},{"key":"9768_CR11","doi-asserted-by":"crossref","unstructured":"Spahr L, Chalandon Y, Terraz S, et al. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS ONE 2013;8(1):e53719","DOI":"10.1371\/journal.pone.0053719"},{"key":"9768_CR12","doi-asserted-by":"crossref","unstructured":"Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135(6):1953\u20131960","DOI":"10.1053\/j.gastro.2008.08.057"},{"key":"9768_CR13","doi-asserted-by":"crossref","unstructured":"Lu Y, Wu D, Wang X, Ward SC, Cederbaum AI. Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. Free Radic Biol Med 2010;49(9):1406\u20131416","DOI":"10.1016\/j.freeradbiomed.2010.07.026"},{"key":"9768_CR14","doi-asserted-by":"crossref","unstructured":"Kono H, Rusyn I, Yin M, et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000;106(7):867\u2013872","DOI":"10.1172\/JCI9020"},{"key":"9768_CR15","doi-asserted-by":"crossref","unstructured":"Kandar R. The ratio of oxidized and reduced forms of selected antioxidants as a possible marker of oxidative stress in humans. Biomed Chromatogr 2016;30(1):13\u201328","DOI":"10.1002\/bmc.3529"},{"key":"9768_CR16","doi-asserted-by":"crossref","unstructured":"Schnabl B. Liver capsule: Mechanisms of alcoholic hepatitis. Hepatology 2016;64(1):276","DOI":"10.1002\/hep.28488"},{"key":"9768_CR17","doi-asserted-by":"crossref","unstructured":"Hirano T, Kaplowitz N, Tsukamoto H, Kamimura S, Fernandez-Checa JC. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology 1992;16(6):1423\u20131427","DOI":"10.1002\/hep.1840160619"},{"key":"9768_CR18","doi-asserted-by":"crossref","unstructured":"Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011;365(19):1781\u20131789","DOI":"10.1056\/NEJMoa1101214"},{"key":"9768_CR19","doi-asserted-by":"crossref","unstructured":"Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O\u2019Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis\u2014a randomised clinical trial. J Hepatol 2006;44(4):784\u2013790","DOI":"10.1016\/j.jhep.2005.11.039"},{"key":"9768_CR20","doi-asserted-by":"crossref","unstructured":"Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007;47(2):277\u2013283","DOI":"10.1016\/j.jhep.2007.03.027"},{"key":"9768_CR21","doi-asserted-by":"crossref","unstructured":"Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol 2012;57(5):1097\u20131109","DOI":"10.1016\/j.jhep.2012.04.041"},{"key":"9768_CR22","doi-asserted-by":"crossref","unstructured":"Mato JM, Corrales FJ, Lu SC, Avila MA. S-adenosylmethionine: a control switch that regulates liver function. FASEB J 2002;16(1):15\u201326","DOI":"10.1096\/fj.01-0401rev"},{"key":"9768_CR23","doi-asserted-by":"publisher","unstructured":"Tkachenko P, Maevskaya M, Pavlov A, Komkova I, Pavlov C, Ivashkin V. Prednisolone plus S-adenosil-l-methionine in severe alcoholic hepatitis. Hepatol Int 2016. doi: 10.1007\/s12072-016-9751-4","DOI":"10.1007\/s12072-016-9751-4"},{"key":"9768_CR24","doi-asserted-by":"crossref","unstructured":"Fernandez-Checa JC, Colell A, Garcia-Ruiz C. S-adenosyl-l-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease. Alcohol 2002;27(3):179\u2013183","DOI":"10.1016\/S0741-8329(02)00229-X"},{"key":"9768_CR25","doi-asserted-by":"crossref","unstructured":"Karaa A, Thompson KJ, McKillop IH, Clemens MG, Schrum LW. S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock 2008;30(2):197\u2013205","DOI":"10.1097\/SHK.0b013e318160f417"},{"key":"9768_CR26","doi-asserted-by":"crossref","unstructured":"Artigas A, Wernerman J, Arroyo V, Vincent JL, Levy M. Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis. J Critic Care 2016;33:62\u201370","DOI":"10.1016\/j.jcrc.2015.12.019"},{"key":"9768_CR27","doi-asserted-by":"crossref","unstructured":"Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30(6):1081\u20131089","DOI":"10.1016\/S0168-8278(99)80263-3"},{"key":"9768_CR28","unstructured":"Testino G, Leone S, Ansaldi F, Borro P. Silymarin and S-adenosyl-L-methionine (SAMe): two promising pharmacological agents in case of chronic alcoholic hepathopathy. A review and a point of view. Minerva Gastroenterol Dietol 2013;59(4):341\u2013356"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9768-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-016-9768-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9768-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T15:18:34Z","timestamp":1657293514000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-016-9768-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["9768"],"URL":"https:\/\/doi.org\/10.1007\/s12072-016-9768-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2016,9,15]]},"assertion":[{"value":"12 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joaquin Cabezas and Ramon Bataller disclose no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This work was supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1U01AA021908-01 and 1U01AA020821). JC was supported by Juan Rodes Scholarship by AEEH (Asociacion Espa\u00f1ola para el Estudio del Higado).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}